A forum representing the Indian biotechnology sector has inked an MoU with Japan's top industry body Forum for Innovative Regenerative Medicine (FIRM) to accelerate research on regenerative medicine. The partnership between the Association of Biotechnology Led Enterprises (ABLE) and FIRM is a unique platform to advance and promote commercialisation of life saving products in regenerative medicine in both the countries. The collaborative programmes between ABLE and FIRM will focus on advancing the individual and common missions by sharing information including technology, policy, partnerships and opportunities such as co-sponsoring meetings and other cooperation based on common concern. The memorandum of understanding (MoU) was signed by P Manohar, Head of the Committee for Regenerative Medicine Group of ABLE and FIRM chairman Yuzo Toda. "The partnership is a step forward to enhance the learning and training on cell and gene treatment leading to enhancement of the cell and gene therapies which help to address major unmet medical needs in India.
We look forward to working with FIRM and contribute towards controlling and curing major human illness," Manohar said. "Our association with ABLE is an opportunity to work towards the advancement of the field and tap on the potential to transform human healthcare," said Takuya Yokokawa of the FIRM.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)